Latest Research, Industry, Medical and Scientific News
New App Supports Nurses to Provide Bladder and Bowel Continence Care
A free app that could boost nurses’ success in managing patients with bladder or bowel incontinence was launched on Monday, marking the beginning of World Continence Week. Those behind the new app said it was a result of a “genuine desire to help people with bladder and bowel symptoms access information and advice that can help”. The CONfidence app offers information, self-care tips and links to local health and support services for the estimated 14 million people in the UK with bladder control problems, and the 6.5 million who have bowel control problems. Read more.
Source: Nursing Times, June 22, 2021
Santex SPA Announces Acquisition of U.S. E-commerce Retailer Parentgiving, Inc.
Santex SPA, a global leader in premier incontinence products and surgical dressing and orthopedic products, announced the acquisition of Parentgiving, Inc., the country’s premier retailer of caregiving products for the aging. The agreement was finalized in June 2020, and the companies have spent the past year integrating operations and developing an expanded portfolio of Parentgiving’s signature Dry Direct incontinence products for expansion in the United States. Read more.
Source: PR Newswire, June 22, 2021
FDA Authorizes Study Exploring Novel Device for Bladder Incontinence
The FDA has approved the launch of an investigational device exemption trial exploring a novel implantable tibial neuromodulation (TNM) device designed to relieve symptoms of bladder incontinence. The trial, known as the TITAN 1 Feasibility Study, is a multicenter, prospective trial aiming to enroll 20 patients at 8 clinical sites in the United States. The patients will have the device implanted in the posterior tibial nerve near the ankle. They will be followed for 12 months to assess the feasibility of the product. Enrollment for the trial is expected to commence in May. Medtronic currently offers several products for bladder control, including the InterStim sacral neuromodulation systems and the NURO percutaneous tibial neuromodulation (PTNM). Read more.
Source: Urology Times, April 27, 2021
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced the commercial launch of GEMTESA® (vibegron) 75 mg tablets, a beta-3 (β3) adrenergic receptor agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. Read more.
Source: Business Wire, April 12, 2021
First Patients Enrolled in Uromedica’s Adjustable Continence Therapy (ACT®) for Female Stress Urinary Incontinence (SUI) Trial
Uromedica, Inc. announces the initiation of its FDA Investigational Device Exemption trial for ACT® to evaluate its safety and efficacy for treatment of female SUI. Stress urinary incontinence is the accidental leakage of urine that can occur when sneezing, coughing, or performing physical activity. The investigational intent of the ACT trial, a post-operatively adjustable, minimally invasive outpatient procedure, is to assess safety and efficacy for women who suffer from moderate or severe SUI. Read more.
Source: Business Wire, March 10, 2021
Isolated and Alone: Nonprofits See Explosion of Need for Adult Incontinence Products
Before the pandemic and when she had the extra money, Lucy Jackson would sometimes go out to buy the adult incontinence products she needed to get through the day and night. But now, worried about catching the coronavirus, she rarely leaves her Newark, New Jersey, boarding house. To get supplies, she relies more on friends, family and the Modestly Cover Diaper Bank of Essex County, New Jersey. “During this pandemic, it’s been very, very difficult,” Jackson, 72, said. Read more.
Source: NBC Universal, March 8, 2021